drugset / Trial / NCT05531656
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Phase 2
Active not recruiting
540 enrolled
Cognition Therapeutics
Alzheimer's Clinical Trials Consortium · collabNational Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Timeline
- Start
- 2023-06-28
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CT1812 | Small molecule | 100 mg | Oral |
| Comparator | CT1812 | Small molecule | 200 mg | Oral |